Literature DB >> 24659891

A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia.

Luca Valenti1, Anna Ludovica Fracanzani1, Paola Dongiovanni1, Serena Rovida1, Raffaela Rametta1, Erika Fatta1, Edoardo Alessandro Pulixi1, Marco Maggioni1, Silvia Fargion1.   

Abstract

AIM: To compare iron depletion to lifestyle changes alone in patients with severe nonalcoholic fatty liver disease (NAFLD) and hyperferritinemia, a frequent feature associated with more severe liver damage, despite at least 6 mo of lifestyle changes.
METHODS: Eligible subjects had to be 18-75 years old who underwent liver biopsy for ultrasonographically detected liver steatosis and hyperferritinemia, ferritin levels ≥ 250 ng/mL, and NAFLD activity score > 1. Iron depletion had to be achieved by removing 350 cc of blood every 10-15 d according to baseline hemoglobin values and venesection tolerance, until ferritin < 30 ng/mL and/or transferrin saturation (TS) < 25%. Thirty-eight patients were randomized 1:1 to phlebotomy (n = 21) or lifestyle changes alone (n = 17). The main outcome of the study was improvement in liver damage according to the NAFLD activity score at 2 years, secondary outcomes were improvements in liver enzymes [alanine aminotransferases (ALT), aspartate aminotransferase (AST), and gamma-glutamyl-transferases (GGT)].
RESULTS: Phlebotomy was associated with normalization of iron parameters without adverse events. In the 21 patients compliant to the study protocol, the rate of histological improvement was higher in iron depleted vs control subjects (8/12, 67% vs 2/9, 22%, P = 0.039). There was a better improvement in steatosis grade in iron depleted vs control patients (P = 0.02). In patients followed-up at two years (n = 35), ALT, AST, and GGT levels were lower in iron-depleted than in control patients (P < 0.05). The prevalence of subjects with improvement in histological damage or, in the absence of liver biopsy, ALT decrease ≥ 20% (associated with histological improvement in biopsied patients) was higher in the phlebotomy than in the control arm (P = 0.022). The effect of iron depletion on liver damage improvement as assessed by histology or ALT decrease ≥ 20% was independent of baseline AST/ALT ratio and insulin resistance (P = 0.0001).
CONCLUSION: Iron depletion by phlebotomy is likely associated with a higher rate of improvement of histological liver damage than lifestyle changes alone in patients with NAFLD and hyperferritinemia, and with amelioration of liver enzymes.

Entities:  

Keywords:  Ferritin; Iron depletion; Nonalcoholic fatty liver disease; Randomized controlled trial

Mesh:

Year:  2014        PMID: 24659891      PMCID: PMC3961977          DOI: 10.3748/wjg.v20.i11.3002

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  32 in total

1.  Venesection therapy of insulin resistance-associated hepatic iron overload.

Authors:  A Guillygomarc'h; M H Mendler; R Moirand; F Lainé; V Quentin; V David; P Brissot; Y Deugnier
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

2.  Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

Authors:  Elisabetta Bugianesi; Nicola Leone; Ester Vanni; Giulio Marchesini; Franco Brunello; Patrizia Carucci; Alessandro Musso; Paolo De Paolis; Lorenzo Capussotti; Mauro Salizzoni; Mario Rizzetto
Journal:  Gastroenterology       Date:  2002-07       Impact factor: 22.682

3.  Liver pathology in genetic hemochromatosis: a review of 135 homozygous cases and their bioclinical correlations.

Authors:  Y M Deugnier; O Loréal; B Turlin; D Guyader; H Jouanolle; R Moirand; C Jacquelinet; P Brissot
Journal:  Gastroenterology       Date:  1992-06       Impact factor: 22.682

4.  Insulin resistance-associated hepatic iron overload.

Authors:  M H Mendler; B Turlin; R Moirand; A M Jouanolle; T Sapey; D Guyader; J Y Le Gall; P Brissot; V David; Y Deugnier
Journal:  Gastroenterology       Date:  1999-11       Impact factor: 22.682

5.  Measurement of liver-iron concentration in needle-biopsy specimens.

Authors:  M Barry; S Sherlock
Journal:  Lancet       Date:  1971-01-16       Impact factor: 79.321

6.  Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity.

Authors:  Jeffrey D Browning; Lidia S Szczepaniak; Robert Dobbins; Pamela Nuremberg; Jay D Horton; Jonathan C Cohen; Scott M Grundy; Helen H Hobbs
Journal:  Hepatology       Date:  2004-12       Impact factor: 17.425

7.  Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis.

Authors:  L Valenti; P Dongiovanni; A L Fracanzani; G Santorelli; E Fatta; C Bertelli; E Taioli; G Fiorelli; S Fargion
Journal:  Dig Liver Dis       Date:  2003-03       Impact factor: 4.088

8.  Excess iron into hepatocytes is required for activation of collagen type I gene during experimental siderosis.

Authors:  R Gualdi; G Casalgrandi; G Montosi; E Ventura; A Pietrangelo
Journal:  Gastroenterology       Date:  1994-10       Impact factor: 22.682

9.  Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver.

Authors:  Elisabetta Bugianesi; Paola Manzini; Sergio D'Antico; Ester Vanni; Filomena Longo; Nicola Leone; Paola Massarenti; Antonio Piga; Giulio Marchesini; Mario Rizzetto
Journal:  Hepatology       Date:  2004-01       Impact factor: 17.425

10.  A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver.

Authors:  Raluca Pais; Fréderic Charlotte; Larissa Fedchuk; Pierre Bedossa; Pascal Lebray; Thierry Poynard; Vlad Ratziu
Journal:  J Hepatol       Date:  2013-05-09       Impact factor: 25.083

View more
  27 in total

1.  Effects of iron supplementation in mice with hypoferremia induced by obesity.

Authors:  Érica Martins Ferreira Gotardo; Cintia Rabelo E Paiva Caria; Caroline Candida de Oliveira; Thalita Rocha; Marcelo Lima Ribeiro; Alessandra Gambero
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-24

Review 2.  Dysregulation of iron and copper homeostasis in nonalcoholic fatty liver.

Authors:  Elmar Aigner; Günter Weiss; Christian Datz
Journal:  World J Hepatol       Date:  2015-02-27

Review 3.  Prevention of hepatocellular carcinoma: Focusing on antioxidant therapy.

Authors:  Koji Miyanishi; Toshifumi Hoki; Shingo Tanaka; Junji Kato
Journal:  World J Hepatol       Date:  2015-03-27

4.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.

Authors: 
Journal:  Diabetologia       Date:  2016-06       Impact factor: 10.122

Review 5.  Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review.

Authors:  Tyler J Severson; Siddesh Besur; Herbert L Bonkovsky
Journal:  World J Gastroenterol       Date:  2016-08-07       Impact factor: 5.742

Review 6.  Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Authors:  Gregory Thomas Brown; David E Kleiner
Journal:  Metabolism       Date:  2015-12-02       Impact factor: 8.694

Review 7.  Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options.

Authors:  Sandra Milic; Ivana Mikolasevic; Irena Krznaric-Zrnic; Marija Stanic; Goran Poropat; Davor Stimac; Vera Vlahovic-Palcevski; Lidija Orlic
Journal:  Drug Des Devel Ther       Date:  2015-08-20       Impact factor: 4.162

Review 8.  Epidemiological associations between iron and cardiovascular disease and diabetes.

Authors:  Debargha Basuli; Richard G Stevens; Frank M Torti; Suzy V Torti
Journal:  Front Pharmacol       Date:  2014-05-20       Impact factor: 5.810

9.  Hepatic iron in African Americans who underwent liver biopsy.

Authors:  James C Barton; Luigi F Bertoli; Thomas J Alford; J Clayborn Barton; Corwin Q Edwards
Journal:  Am J Med Sci       Date:  2015-01       Impact factor: 2.378

Review 10.  Iron Reshapes the Gut Microbiome and Host Metabolism.

Authors:  Amy Botta; Nicole G Barra; Nhat Hung Lam; Samantha Chow; Kostas Pantopoulos; Jonathan D Schertzer; Gary Sweeney
Journal:  J Lipid Atheroscler       Date:  2021-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.